Literature DB >> 23324090

Selective use of the insulin tolerance test to diagnose hypopituitarism.

S Sarlos1, W J Inder.   

Abstract

The insulin tolerance test is considered the gold standard for assessing the hypothalamic-pituitary-adrenal and growth hormone (GH) axes, but its use varies considerably among different endocrine units. We recommend using the insulin tolerance test to assess the hypothalamic-pituitary-adrenal axis within 3 months of pituitary surgery, where adrenocorticotropic hormone 1-24 testing is equivocal, and to assess for GH deficiency where the patient is being considered for GH replacement therapy. We also discuss safety issues, how to ensure adequate hypoglycaemia and possible alternative tests, such as the overnight metyrapone test and glucagon test.
© 2013 The Authors; Internal Medicine Journal © 2013 Royal Australasian College of Physicians.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23324090     DOI: 10.1111/imj.12011

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  3 in total

1.  Recovery Room Cortisol Predicts Long-Term Glucocorticoid Need After Transsphenoidal Surgery for Pituitary Tumors.

Authors:  Amro Qaddoura; Tenzin N Shalung; Michael P Meier; Jeannette Goguen; Rowan Jing; Stanley Zhang; Kalman Kovacs; Michael D Cusimano
Journal:  Neurosurgery       Date:  2019-03-01       Impact factor: 4.654

2.  A Comparison of the Blood Glucose, Growth Hormone, and Cortisol Responses to Two Doses of Insulin (0.15 U/kg vs. 0.10 U/kg) in the Insulin Tolerance Test: A Single-Centre Audit of 174 Cases.

Authors:  Phillip Yeoh; Andrew A Dwyer; Ella Anghel; Pierre M Bouloux; Bernard Khoo; Shern Chew; Florian Wernig; Paul Carroll; Simon J B Aylwin; Stephanie E Baldeweg; William Drake; Jeannie Todd; Lindiwe Mangena; Ashley Grossman
Journal:  Int J Endocrinol       Date:  2022-02-08       Impact factor: 2.803

Review 3.  Impaired Pituitary Axes Following Traumatic Brain Injury.

Authors:  Robert A Scranton; David S Baskin
Journal:  J Clin Med       Date:  2015-07-13       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.